Filing Details

Accession Number:
0001209191-22-058795
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-11-25 16:15:51
Reporting Period:
2022-11-22
Accepted Time:
2022-11-25 16:15:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787297 Passage Bio Inc. PASG Biological Products, (No Disgnostic Substances) (2836) 822729751
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1799814 Alexandros Fotopoulos One Commerce Square
2005 Market Street, 39Th Floor
Philadelphia PA 19103
Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-11-22 12,500 $0.00 23,965 No 4 M Direct
Common Stock Disposition 2022-11-22 3,720 $1.33 20,245 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-11-22 12,500 $0.00 12,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
37,500 No 4 M Direct
Footnotes
  1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  2. The reported total includes 3,082 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
  3. The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
  4. The reported transaction represents the settlement of restricted stock units which vested on June 15, 2022 but for which settlement was delayed due to an inadvertent administrative error.
  5. 1/4 of the RSUs vested on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
  6. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.